Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, continues to progress its RNA-based therapeutic pipeline with multiple programs in obesity, genetic liver and lung diseases, neuromuscular disorders, and neurodegeneration. With a proprietary platform focused on RNA editing and interference, the company has outlined a series of upcoming clinical milestones that could shape its trajectory over the next 12-18 months.
Obesity Program: WVE-007 Shows Durable Target Engagement
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com